← Leaderboards
Sharon L Reed
University Of California San Diego
$12,983,856
Attributed
$12,983,856
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$12,983,856 · 7
By mechanism
U01$9,238,655 · 2
R01$1,928,955 · 2
P01$1,254,186 · 1
R21$336,020 · 1
R34$226,040 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Lars Eckmann$20,489,190
- Frances D. Gillin$6,836,341
- Kim Elaine Barrett$5,025,974
- Vivian Y. H. Hook$23,603,887
Others in their field
Top investigators on “Entamoeba Histolytica”
- William A Petri · University Of Virginia$21,488,540
- Upinder Singh · Stanford University$13,924,073
- Christopher Fox · Access To Advanced Health Institute$8,540,962
- Lars Eckmann · University Of California San Diego$8,004,561
- Joel F Herbein · Techlab, Inc.$6,789,761
- Benjamin F Arnold · University Of California Berkeley$6,642,383
Research focus
Entamoeba HistolyticaAmebiasisCysteine EndopeptidasesEnzyme ActivityIntracellular ParasitismHost Organism InteractionPolymerase Chain ReactionPharmaceutical PreparationsHigh Performance Liquid ChromatographyParasitesAdverse EffectsAntiparasitic AgentsGrantIn VitroInfectionLeadDesignGiardiaCystImmunoglobulin AImidazoleBaseNovel TherapeuticsProtozoa
Grant awards (26)
Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa$600,376
U01 · FY2018 · AI · contact PI
Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa$611,157
U01 · FY2017 · AI · contact PI
Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa$607,119
U01 · FY2016 · AI · contact PI
Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa$629,075
U01 · FY2015 · AI · contact PI
Novel Therapeutics for Class B Protozoa$1,371,646
U01 · FY2012 · AI · contact PI
Planning Grant for the Efficacy of Auranofin for the Treatment of Amebiasis$226,040
R34 · FY2012 · AI · contact PI
Novel Therapeutics for Class B Protozoa$1,366,784
U01 · FY2011 · AI · contact PI
Novel Therapeutics for Class B Protozoa$1,380,550
U01 · FY2010 · AI · contact PI
Novel Therapeutics for Class B Protozoa$1,371,947
U01 · FY2009 · AI · contact PI
Novel Therapeutics for Class B Protozoa$1,300,001
U01 · FY2008 · AI · contact PI
Genetic Manipulation of Entamoeba Virulence$304,000
R01 · FY2005 · AI
Genetic Manipulation of Entamoeba Virulence$304,000
R01 · FY2004 · AI
Genetic Manipulation of Entamoeba Virulence$266,000
R01 · FY2003 · AI
Genetic Manipulation of Entamoeba Virulence$226,100
R01 · FY2002 · AI
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$221,831
P01 · FY2002 · DK
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$221,831
P01 · FY2002 · DK
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$221,831
P01 · FY2002 · DK
PROTEASE INHIBITORS--NOVEL DRUG THERAPY FOR T GONDII$287,544
R01 · FY2001 · AI
Genetic Manipulation of Entamoeba Virulence$265,854
R01 · FY2001 · AI
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$221,831
P01 · FY2001 · DK
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$221,831
P01 · FY2001 · DK
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$0
P01 · FY2001 · DK
CYSTEINE PROTEINASES AND VIRULENCE OF E. HISTOLYTICA$336,020
R21 · FY2000 · AI
PROTEASE INHIBITORS--NOVEL DRUG THERAPY FOR T GONDII$275,457
R01 · FY2000 · AI
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$145,031
P01 · FY2000 · DK
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES$0
P01 · FY2000 · DK